Biodefense vaccines are a critical component of preparedness strategies against biological threats, including potential bioterrorism attacks or naturally occurring infectious diseases with epidemic potential. These vaccines are designed to protect individuals and populations from specific pathogens that could be used intentionally or emerge unexpectedly. Biodefense vaccines target a range of potential biological weapons or infectious agents, such as anthrax, smallpox, botulism, and various viral hemorrhagic fevers. They are developed and stockpiled to ensure a rapid and effective response in the event of an outbreak or bioterrorism incident. Research and development in biodefense vaccines involve advanced technologies, including recombinant DNA techniques and novel vaccine platforms. These vaccines are rigorously tested for safety and efficacy, and their distribution is strategically managed to address specific threat scenarios. Biodefense vaccines are a critical component of national security and public health efforts, aiming to mitigate the impact of intentional or accidental releases of dangerous pathogens. Their development and deployment require collaboration between governments, research institutions, and pharmaceutical companies to enhance global readiness for potential biowarfare or infectious disease emergencies.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia